Real-world analyses of bispecific antibodies and CAR-T cell therapy in&#xa0;relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Multiple Myeloma (MM)

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Blood Cancer J

Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ

doi: 10.1038/s41408-026-01469-z

Lymphoma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Br J Haematol

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW

doi: 10.1111/bjh.70632

Multiple Myeloma (MM)

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Clin Cancer Res

Suvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K

doi: 10.1158/1078-0432.CCR-25-4068

Multiple Myeloma (MM)

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Ann Hematol

Benda M, Reimann P, Willenbacher W, Gunsilius E, Weisel K, Strassl I, Krauth MT, Knop S, Winder T, Steiner N

doi: 10.1007/s00277-026-07140-8

Multiple Myeloma (MM)

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

Am J Hematol

Janakiram M, Tan CR, Mian H, Huang CY, Popat R, Martínez-Lopez J, Kastritis E, Chng WJ, Kapoor P, Dave M, Bal S, Garderet L, Corraes AMS, Riedhammer C, Steinbrunn T, Corona M, Nagarajan C, Einsele H, Martin T, Krishnan A, Lin Y

doi: 10.1002/ajh.70376

Multiple Myeloma (MM)

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent

Adv Ther

Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martínez López J, Rodríguez-Otero P, Dytfeld D, Jakubowiak A, Schinke C, Besemer B, Anguille S, Manier S, Rasche L, Teipel R, Scheid C, Pawlyn C, Cavo M, Diels J, Ghilotti F, Lau BW, Renaud T, Orel O, Ong F, Ramos DF, Ammann E, Parekh T, Albrecht C, Weisel K, Mateos MV

doi: 10.1007/s12325-025-03409-y

Multiple Myeloma (MM)

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Bone Marrow Transplant

Rasche L, Krauth MT, Agis H, Renner C, Strassl I, Teipel R, Vučinić V, Weisel K, Willenbacher W, Raab MS

doi: 10.1038/s41409-026-02905-1

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Lymphoma

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

Br J Haematol

Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S, ATL working groups of the Japanese Society for Transplantation and Cellular Therapy

doi: 10.1111/bjh.70631

Oncology · Hematology

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Related content

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience